Markets· August 17, 2026 at 03:47 p.m.
Greenhaven Road Capital Realizes Short-Term Gain from Liquidia Corporation, Future Investment to Be Revisited
Key takeaways
- Greenhaven Road Capital achieved a net return of approximately 11% in Q2 2026
- Liquidia Corporation (LQDA) is a biopharmaceutical company specializing in rare cardiopulmonary diseases
- Greenhaven Road Capital realized a short-term gain from LQDA before a verdict in a patent dispute
Greenhaven Road Capital, an investment management firm, announced a net return of approximately 11% in the second quarter of 2026. The company plans to lower portfolio concentration and increase investments with near-term catalysts, while maintaining a focus on owning strong businesses and challenging consensus views. Among the key changes, Greenhaven Road Capital has realized a short-term gain from Liquidia Corporation (LQDA), a biopharmaceutical company specializing in rare cardiopulmonary diseases. The firm purchased shares of LQDA anticipating gains even after an adverse trial outcome, which led to a 30% appreciation before a verdict.
